Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 15Lymphoid 15Plasma cell 1Dermatologic 1Classical hematology 1

Conditions

Anemia, Refractory, with Excess of Blasts 271Leukemia, Myeloid, Acute 258Myelodysplastic Syndromes 254Anemia 245Leukemia 228Neoplasms 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 182Leukemia, Myelomonocytic, Chronic 151Multiple Myeloma 138Venous Thromboembolism 137Myeloproliferative Disorders 131Leukemia, Lymphocytic, Chronic, B-Cell 126Lymphoma 119Lymphoma, Non-Hodgkin 118Thrombocytopenia 117Hodgkin Disease 103Anemia, Aplastic 97Febrile Neutropenia 86Hematologic Neoplasms 82Anemia, Refractory 82Primary Myelofibrosis 81Lymphoma, Follicular 81Congenital Abnormalities 81Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73Blast Crisis 72Leukemia, Myeloid, Accelerated Phase 69Lymphoma, Mantle-Cell 68Neoplasms, Plasma Cell 66Myelodysplastic-Myeloproliferative Diseases 65

Interventions

obinutuzumab 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Classical hematology × Clear all
NCT03010358 2023-08-08

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

OHSU Knight Cancer Institute

Phase 1/2 Completed
24 enrolled 16 charts
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡